CCA
RIGL icon

Column Capital Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Column Capital Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-31
Closed -$400 – 820
2023
Q2 		$400 Hold
31
– – ﹤0.01% 784
2023
Q1 		$409 Hold
31
– – ﹤0.01% 800
2022
Q4 		$465 Buy
+31
New +$284 ﹤0.01% 796

Other funds holding RIGL

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Column Capital Advisors's RIGL Position: Q3 2023 in Review

Column Capital Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 31 shares — an estimated $400 sold.

Column Capital Advisors first reported a position in RIGL in Q4 2022 and held it in 3 quarters. The position peaked at $465 in Q4 2022. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

  • Column Capital Advisors reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Column Capital Advisors sold 31 Rigel Pharmaceuticals shares in Q3 2023, an estimated $400.
  • Column Capital Advisors first reported a position in Rigel Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Column Capital Advisors's Rigel Pharmaceuticals position peaked at $465 in Q4 2022.
  • 106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.